These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 20113148)
21. Galantamine: a review of its use in Alzheimer's disease. Scott LJ; Goa KL Drugs; 2000 Nov; 60(5):1095-122. PubMed ID: 11129124 [TBL] [Abstract][Full Text] [Related]
22. The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease. Dev H; Agius M; Zaman R Psychiatr Danub; 2010 Jun; 22(2):367-9. PubMed ID: 20562785 [TBL] [Abstract][Full Text] [Related]
23. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Tayeb HO; Yang HD; Price BH; Tarazi FI Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801 [TBL] [Abstract][Full Text] [Related]
24. An update on the pharmacology of galantamine. Villarroya M; García AG; Marco-Contelles J; López MG Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006 [TBL] [Abstract][Full Text] [Related]
25. Current status and new developments with galantamine in the treatment of Alzheimer's disease. Tariot P Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333 [TBL] [Abstract][Full Text] [Related]
26. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. Lilienfeld S CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686 [TBL] [Abstract][Full Text] [Related]
27. Alzheimer's dementia: current data review. Uzun S; Kozumplik O; Folnegović-Smalc V Coll Antropol; 2011 Dec; 35(4):1333-7. PubMed ID: 22397284 [TBL] [Abstract][Full Text] [Related]
28. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Grossberg GT Int Psychogeriatr; 2002; 14 Suppl 1():27-49. PubMed ID: 12636179 [TBL] [Abstract][Full Text] [Related]
30. The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. Dengiz AN; Kershaw P CNS Spectr; 2004 May; 9(5):377-92. PubMed ID: 15115951 [TBL] [Abstract][Full Text] [Related]
31. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease. Haake A; Nguyen K; Friedman L; Chakkamparambil B; Grossberg GT Expert Opin Drug Saf; 2020 Feb; 19(2):147-157. PubMed ID: 31976781 [No Abstract] [Full Text] [Related]
32. [Treatment of Alzheimer's disease: the current situation?]. Jacquy J Rev Med Brux; 2010 Sep; 31(4):357-62. PubMed ID: 21089415 [TBL] [Abstract][Full Text] [Related]
33. Switching previous therapies for Alzheimer's disease to galantamine. Ferris SH Clin Ther; 2001; 23 Suppl A():A3-7. PubMed ID: 11396869 [TBL] [Abstract][Full Text] [Related]
34. Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine*. Nieoullon A; Bentué-Ferrer D; Bordet R; Tsolaki M; Förstl H Curr Med Res Opin; 2008 Dec; 24(12):3357-67. PubMed ID: 19032118 [TBL] [Abstract][Full Text] [Related]
35. The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease. Farlow MR Lancet Neurol; 2009 Jan; 8(1):22-3. PubMed ID: 19042160 [No Abstract] [Full Text] [Related]
36. Galantamine: a new treatment for Alzheimer's disease. Wilkinson DG Expert Rev Neurother; 2001 Nov; 1(2):153-9. PubMed ID: 19811027 [TBL] [Abstract][Full Text] [Related]